Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Labs offers 1,500 recombinant proteins
Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Research & Development
Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar launches new UNHT series for next-generation nanoindentation

Read more
Anton Paar introduces the new UNHT Series, a new generation of nanoindentation systems designed to deliver reliable results, faster workflows, and greater versatility across a wide range of materials

Trending Articles

  1. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  2. Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
  3. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes
  4. ADC development demands a new level of bioconjugation expertise Why growing ADC complexity is placing greater demands on bioconjugation and manufacturing expertise
  5. Making blister package integrity testing decisions that QA can use A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions

You may also like

Research & Development
Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar introduces the new UNHT Series, a new generation of nanoindentation systems designed to deliver reliable results, faster workflows, and greater versatility across a wide range of materials
Research & Development
Rethinking the route to first-in-human studies

Rethinking the route to first-in-human studies

For sponsors, development activities and fragmented clinical supply can slow the path from candidate selection to first-in-human (FIH) dosing. A more integrated approach can reduce avoidable complexity while preserving the flexibility needed for early clinical programmes
Research & Development
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
Research & Development
Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments
Manufacturing
Making blister package integrity testing decisions that QA can use

Making blister package integrity testing decisions that QA can use

A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions
Manufacturing
FDA inspection readiness: Preparing for surveillance and pre-approval inspections

FDA inspection readiness: Preparing for surveillance and pre-approval inspections

Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
Manufacturing
ADC development demands a new level of bioconjugation expertise

ADC development demands a new level of bioconjugation expertise

Why growing ADC complexity is placing greater demands on bioconjugation and manufacturing expertise
Subscribe now